Find drug development pipeline and deal Updates information

Lead Product(s): Ruxolitinib

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.

Lead Product(s): Baricitinib, Corticosteroid

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Study met primary endpoint of at least 75% improvement of skin inflammation. Safety profile was consistent with the known safety findings of baricitinib in atopic dermatitis.

Lead Product(s): Prabotulinumtoxin A

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Primary endpoint of non-Inferiority achieved with responder rates* of 65.02% for PrabotulinumtoxinA and 62.56% for OnabotulinumtoxinA at week 4.

Lead Product(s): Tapinarof

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Japan Tobacco

Deal Size: $113.0 million Upfront Cash: $60.0 million

Deal Type: Licensing Agreement January 15, 2020

Details:

A license agreement to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis.

Lead Product(s): EB-101

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

Many patients selected for registration have completed the Stanford pre-screening process, and the Company expects to treat the first patient in the VIITALTM trial in the first quarter of 2020.

Lead Product(s): Risankizumab

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

SKYRIZI™ (risankizumab) met both primary and all secondary endpoints in a head-to-head, open-label study versus Cosentyx® (secukinumab).

Lead Product(s): Sofpironium bromide

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

The application for sofpironium bromide in Japan involves data from the Phase 3 study in Japan, targeting patients with primary axillary hyperhidrosis, in which positive results were obtained.

Lead Product(s): Lebrikizumab

Therapeutic Area: Dermatology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Eli Lilly and Company

Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

Deal Type: Acquisition January 10, 2020

Details:

Lilly gets Dermira’s experimental treatment for atopic dermatitis, as well as an approved medicated cloth for excessive armpit sweating.